Shots:

• The approval is based on P-III C-AXSPAND study assessing Cimzia (400mg) vs PBO + common background medications in 317 patients with severe active nr-axSpA with an objective sign of inflammation as indicated by elevated CRP/ MRI evidence who had an inadequate response to/ or intolerant to NSAIDs
• The P-III C-AXSPAND study results: met its 1EPs & 2EPs i.e- improvement in ASDAS-MI @52wks. (47.2% vs 7.0%) & improvement in ASAS40 @12wks. (47.8% vs 11.4%)
• Cimzia is the only Fc-free- PEGylated anti-TNF- having high affinity for human TNF-alpha and is indicated for reducing signs and symptoms in adult patients with active AS. The approval marks the fifth indication for Cimzia

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: StraitTimes